Helixgate https://validator.w3.org/feed/docs/rss2.html Home Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s next Monoclonal Antibodies: Unlocking Cost and Efficiency Gains in Downstream Processing Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific STAT+: An insider reveals the real goals of prior authorization Sun Pharma beams up Organon in $11.75B acquisition Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi Genetic Medicine Delivery Enhanced by Producer Cell Modifications STAT+: Astellas retries XLMTM gene therapy after deaths Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax Intellia heads to FDA after notching first late-stage win for in vivo gene editor Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial Veradermics wins at growing hair with oral Rogaine in first key test as a public company J&J puts blockbuster blood thinner Xarelto on TrumpRx STAT+: Zap in a cap: How one neurotech startup is using a hat to treat depression Abdominal Contractions May Drive Brain Fluid Flow, Aiding in Neural Waste Clearance What happened to Covid? Sun Pharma to buy Organon for $11.75B in major portfolio expansion Turn health data into impact: Browns University’s online master in biostatistics & health data science Gene therapy leaders aim to help more Baby KJs with novel regulatory models Investment in UK biotechs shows early signs of recovery, report says UCSF, Par Health hit with FDA warning letters for environmental monitoring issues STAT+: Doctor, wife of acting U.S. attorney general appointed to NIH advisory council StockWatch: Trump Order Lifts Psychedelic Drug Shares Nancy Cox, a CDC veteran and a stalwart in global flu research, dies at 77 Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more Thermo Fisher sees higher Q1 earnings amid strong biopharma demand Engineered conductive pili enable high-efficiency photosynthetic electron extraction in biophotovoltaics AI Learns to Predict Breast Cancer Risk from How Single Cells Respond to Pressure Single-Cell Atlas of the Prenatal Brain Reveals How Down Syndrome Reshapes Development STAT+: FDA to speed up review of three psychedelics as mental health treatments STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B FDA unveils three psychedelic-focused commissioner vouchers STAT+: Utah medical board calls for immediate suspension of state’s AI doctor experiment AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains STAT+: Up and Down the Ladder: The latest comings and goings Sanofi MS drug rejected in US gets an endorsement in Europe FDA awards priority vouchers to 3 undisclosed companies for investigational psychedelics Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push Avalyn plots $182M IPO; WHO prequalifies Novartis’ malaria drug Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy International childhood vaccine campaign grows STAT+: Sanofi MS drug gets positive review in Europe following FDA BioSpace elevates journalism as biopharma evolves in the Trump era Daiichi Sankyo shares slip after delaying annual earnings report